What happened with GRFS today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Grifois collects plasma, mainly through its own donation centers, then separates and purifies the proteins into medicines. These treatments serve patients with immune deficiencies and other serious conditions. Plasma-derived medicines generate the vast majority of revenue; immunoglobulins, including Gamunex-C and Xembify, account for most company sales.
Hospitals, specialty pharmacies and distributors buy its products. In the United States, group purchasing organizations negotiate prices and supply volumes for member hospitals, and Grifois sells to authorized distributors that resell to those members. In Europe, most medicine sales go directly to hospitals. The United States is its main market, and pricing and insurance reimbursement affect access to its treatments.
The business depends on healthy donors supplying enough plasma, particularly in the United States, and on how much usable protein Grifois can extract from it. Products sold in the United States must use plasma collected at FDA-approved centers. Collection centers and manufacturing plants must maintain regulatory approval and comply with manufacturing-quality standards to keep operating.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Grifols’ results hinge on immunoglobulin demand and plasma collection costs, with CSL Behring, absent from this list, a key rival across its core plasma therapies.
Takeda competes with Grifols to sell plasma-derived medicines for immunoglobulin and alpha-1 antitrypsin treatment, and both depend on plasma availability and collection costs. Watch Takeda’s immunoglobulin pricing: Grifols says competitors’ discounts can force it to lower prices or lose sales.
ADMA Biologics, Inc. both competes with Grifols in intravenous immunoglobulins for patients with primary immunodeficiency and pays Grifols for plasma rich in RSV antibodies to make ASCENIV. Watch its ASCENIV plasma purchases: the agreement requires Grifols to supply at least 35,000 liters annually through September 2039.
Kamada Ltd competes with Grifols in specialty plasma medicines, including treatments that replace deficient alpha-1 antitrypsin, selling directly and through partners and distributors. Its GLASSIA sales offer a focused view of the treatment market in which Grifols is one of Kamada’s two main rivals.
argenx sells VYVGART treatments that compete with Grifols’ immunoglobulins for patients with chronic inflammatory demyelinating polyneuropathy (CIDP) and other overlapping conditions. Watch VYVGART’s CIDP sales and reimbursement agreements: CIDP is one of the patient groups supporting Grifols’ immunoglobulin growth.
QuidelOrtho Corporation competes with Grifols to sell transfusion tests to blood banks, but also buys the test ingredients known as antigens from Grifols under a multi-year agreement making Grifols its exclusive supplier. Watch QuidelOrtho’s donor-screening business for a read on demand for these ingredients, which Grifols continues supplying after their joint business arrangement ended effective January 1, 2026.
Fed Interest Rate Decision
Grifols’ variable-rate New Credit Facilities link U.S. interest-rate decisions to the cash it pays to service debt and to its net income.
Expected4.0%Last release4.0%
If it comes in above expectations
If the Fed sets rates above expectations, interest costs on debt that reprices may rise, leaving Grifols with less cash after debt service and reducing net income.
If it comes in below expectations
If the Fed sets rates below expectations, interest costs on debt that reprices may ease, leaving Grifols with more cash after debt service and supporting net income.
Takeda Pharmaceutical Company Limited earningsTAK
Takeda competes with Grifols for customers buying plasma medicines such as immunoglobulins, and its report will show how demand and price competition in that shared market are changing.
Look at Takeda’s immunoglobulin sales and whether growth comes with price cuts. Strong demand without discount-led gains would suggest less pricing pressure on Grifols. If sales growth relies on discounts, Grifols may have to lower prices or risk losing sales to retain customers.
ADMA Biologics, Inc. earningsADMA
ADMA Biologics’ report can show demand for the RSV-antibody-rich plasma Grifols supplies for ASCENIV, making it a read on a sales channel for Grifols.
Watch ADMA’s ASCENIV business and any indications of purchasing the related plasma. A stronger business would suggest support for demand for Grifols’ supply; a weaker one would suggest limited demand through this channel. ADMA’s results reflect its own product and customers, not Grifols’ overall plasma demand.
QuidelOrtho Corporation earningsQDEL
QuidelOrtho Corporation’s report will show demand in its blood-screening business; Grifols remains its exclusive antigen supplier, making that business a read on their supply relationship.
Look at QuidelOrtho’s blood-donation screening business. Stronger activity would suggest firmer demand for the antigens it uses, supporting Grifols’ supply relationship; weaker activity would point to softer demand through that channel. QuidelOrtho also competes with Grifols in transfusion testing, but that competition does not determine antigen demand.
Grifois, S.A. earningsThis company
Grifols earns most of its revenue from plasma medicines, and this report will show whether growth in key products such as immunoglobulins can withstand pressure on gross margin from plasma costs and pricing.
Read Biopharma sales growth alongside gross margin. Growing sales with a stable or higher margin would show that demand for key products and control of plasma costs are supporting growth. Slowing sales or a falling margin would show that pricing, product mix or plasma costs are offsetting demand, calling the quality of Grifols’ growth into question.
